Biogen believes that its Imraldi adalimumab biosimilar is outperforming other rivals to AbbVie’s Humira reference biologic in Europe. “Our data indicate that Imraldi is the market-leading Humira biosimilar in Europe,” chief financial officer Jeff Capello told investors.
Having developed the biosimilar through its Samsung Bioepis joint venture with Samsung Biologics, Biogen launched Imraldi in Europe on 17 October last year, immediately upon expiry of Humira’s supplementary protection certificate. The biosimilar brand generated sales of $16.7m between mid-October and the end of December last year
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?